![]() | You can help expand this article with text translated from the corresponding article in Russian. (June 2020) Click [show] for important translation instructions.
|
![]() | This article needs more reliable medical references for verification or relies too heavily on primary sources. (July 2020) | ![]() |
![]() | |
![]() | |
Clinical data | |
---|---|
Trade names | Arbidol |
Other names | AR-1I9514, Russian: Арбидол, Chinese: 阿比朵尔.[citation needed] |
Pregnancy category |
|
Routes of administration | By mouth (hard capsules, tablets) |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 40% |
Metabolism | Hepatic, CYP3A4[3][4] |
Elimination half-life | 17–21 hours[3][4] |
Excretion | 40% excrete as unchanged umifenovir in feces (38.9%) and urine (0.12%)[5] |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
PDB ligand | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.247.800 |
Chemical and physical data | |
Formula | C22H25BrN2O3S |
Molar mass | 477.42 g·mol−1 |
3D model (JSmol) | |
| |
| |
![]() ![]() |
Umifenovir, sold under the brand name Arbidol, is sold and used as an antiviral medication for influenza in Russia and China. The drug is manufactured by Pharmstandard (Russian: Фармстандарт). It is not approved by the U.S. Food and Drug Administration (FDA) for the treatment or prevention of influenza.[6]
pharmk1
was invoked but never defined (see the help page).pharmk2
was invoked but never defined (see the help page).